Literature DB >> 31302856

Radiofrequency identification tag localization is comparable to wire localization for non-palpable breast lesions.

Caroline McGugin1, Tara Spivey1, Suzanne Coopey1, Barbara Smith1, Bridget Kelly1, Michele Gadd1, Kevin Hughes1, Brian Dontchos2, Michelle Specht3.   

Abstract

PURPOSE: Radiofrequency identification (RFID) tag localization (TL) is a technique of localizing non-palpable breast lesions that can be performed prior to surgery. We sought to evaluate whether TL is comparable to wire localization (WL) in regard to specimen size, operative time, and re-excision rate.
METHODS: A retrospective cohort analysis was performed on TL and WL excisional biopsies and lumpectomies performed by 5 surgeons at 2 institutions. Cases were stratified by surgery type and surgical indication. Associations between localization technique and specimen volume, operative time, and re-excision rate were assessed by univariate and multivariate analyses.
RESULTS: A total of 503 procedures were included, 147 TL (29.2%) and 356 WL (70.8%). Nineteen (12.9%) RFID tags were placed before surgery, ranging 1-22 days. All intended targets were removed. TL and WL excisional biopsy and lumpectomy specimen volumes were similar (p = 0.560 and 0.494). TL and WL excisional biopsy and lumpectomy + SLNB operative times were similar (p = 0.152 and 0.158), but TL lumpectomies without SLNB took longer than WL (57 min vs 49 min; p = 0.027). Re-excision rates were similar by surgical procedure (p = 0.615), surgical indication (DCIS p = 0.145; invasive carcinoma p = 0.759), and confirmed by multivariable analysis (OR 0.754, 95% CI 0.392-1.450; p = 0.397).
CONCLUSIONS: TL has similar surgical outcomes to WL with added benefit that TL can occur prior to the day of surgery. TL is an acceptable alternative to WL and should be considered for non-palpable breast lesions.

Entities:  

Keywords:  Non-palpable breast lesions; Tag localization; Wireless localization

Mesh:

Year:  2019        PMID: 31302856     DOI: 10.1007/s10549-019-05355-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  6 in total

1.  Combined LOCalizer™ and Intraoperative Ultrasound Localization: First Experience in Localization of Non-palpable Breast Cancer.

Authors:  Simona Parisi; Roberto Ruggiero; Giorgia Gualtieri; Mariachiara Lanza Volpe; Serena Rinaldi; Giusiana Nesta; Lidija Bogdanovich; Francesco Saverio Lucido; Salvatore Tolone; Domenico Parmeggiani; Claudio Gambardella; Ludovico Docimo
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

2.  Evaluation of a Wireless Localization System for Nonpalpable Breast Lesions - Feasibility and Cost-effectiveness in Everyday Clinical Routine.

Authors:  Patrik Pöschke; Julius Emons; Felix Heindl; Rüdiger Schulz-Wendtland; Sebastian Jud; Ramona Erber; Carolin C Hack; Caroline Preuss; Annika Behrens
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

3.  Wireless Breast Localization Using Radio-frequency Identification Tags: The First Reported European Experience in Breast Cancer.

Authors:  Umar Wazir; Salim Tayeh; Nicholas Perry; Michael Michell; Anmol Malhotra; Kefah Mokbel
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

4.  Invited Discussion on: Clinical and MRI Evaluation of Silicone Gel Implants with RFID-M Traceability System: A Prospective Controlled Cohort Study Related to Safety and Image Quality in MRI Follow-Up.

Authors:  Fereydoun D Parsa; Dylan Singh
Journal:  Aesthetic Plast Surg       Date:  2021-06-28       Impact factor: 2.326

5.  A multicenter prospective cohort study to evaluate feasibility of radio-frequency identification surgical guidance for nonpalpable breast lesions: design and rationale of the RFID Localizer 1 Trial.

Authors:  Bianca M den Dekker; Anke Christenhusz; Thijs van Dalen; Lisa M Jongen; Margreet C van der Schaaf; Anneriet E Dassen; Ruud M Pijnappel
Journal:  BMC Cancer       Date:  2022-03-22       Impact factor: 4.430

Review 6.  Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps, and Rationale for the EUBREAST-03 AXSANA Study.

Authors:  Maggie Banys-Paluchowski; Maria Luisa Gasparri; Jana de Boniface; Oreste Gentilini; Elmar Stickeler; Steffi Hartmann; Marc Thill; Isabel T Rubio; Rosa Di Micco; Eduard-Alexandru Bonci; Laura Niinikoski; Michalis Kontos; Guldeniz Karadeniz Cakmak; Michael Hauptmann; Florentia Peintinger; David Pinto; Zoltan Matrai; Dawid Murawa; Geeta Kadayaprath; Lukas Dostalek; Helidon Nina; Petr Krivorotko; Jean-Marc Classe; Ellen Schlichting; Matilda Appelgren; Peter Paluchowski; Christine Solbach; Jens-Uwe Blohmer; Thorsten Kühn
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.